All In Biotech

Drug Trial Radar · NCT07623486

Trial of HSK44459 Cream for the Management Plaque Psoriasis

A Randomized, Double-Blind, Vehicle-Controlled Phase I/II Clinical Study of HSK44459 Cream in Healthy Subjects and Patients With Plaque Psoriasis

Last checked: Nov 19, 2026Latest source record: Jun 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingRandomized with 180 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

180

Planned (sponsor's estimate)

Start

May 22, 2026

Primary completion

Mar 2027

Study completion Jun 2027

Sponsor

Sponsor type
Industry
First posted
Jun 3, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

Phase I Study Objectives: * Primary: Assess the safety and tolerability of HSK44459 cream in 10 healthy adult participants and 10 patients with plaque psoriasis. * Secondary: Evaluate the pharmacokinetic (PK) profile of HSK44459 cream in the same populations (healthy adults and plaque psoriasis patients). Participant Allocation: \- 10 healthy adults and 10 plaque psoriasis patients are enrolled. Participants are randomized to either the HSK44459 cream group (8 per population) or the vehicle (placebo - like) control group (2 per population). Treatment Schedule: * Day 1: Single - dose administration (one application). * Days 2-3: Washout period (no medication). * Days 4-9: Twice - daily administration. * Day 10: One application. Phase II Study Objectives: * Primary: Conduct a preliminary evaluation of the efficacy of HSK44459 cream in treating plaque psoriasis. * Secondary: Assess the safety and tolerability of HSK44459 cream in plaque psoriasis patients. Evaluate the PK profile of HSK44459 cream in plaque psoriasis patients. Participant Allocation: \- 160 plaque psoriasis patients are enrolled and randomized in a 1:1:1:1 ratio to four groups: 1% HSK44459 cream (40 patients), 0.3% HSK44459 cream (40 patients), 0.1% HSK44459 cream (40 patients), or vehicle control (40 patients). Treatment Schedule: Phase II: The study consists of three phases (screening, treatment, and follow - up) * Screening Period (D - 28 to D - 1): Eligible plaque psoriasis patients sign an informed consent form and complete screening assessments to establish baseline data. * Treatment Period (W1D1 to W9D1 ± 3 days): After baseline evaluation, eligible patients are randomized. The first dose of the study drug is administered on W1D1, with twice - daily dosing for 8 weeks. Patients return to the study center at W3D1 ± 3, W5D1 ± 3, W7D1 ± 3, W9D1 ± 3, and W11D1 ± 3 for scheduled assessments and procedures. * Follow - up Period (W9D1 ± 3 days to W11D1 ± 3 days, within 14 days after the last dose): Adverse events and concomitant medications are collected. A final safety visit (W11D1 ± 3 days) includes additional assessments and procedures. In summary, this trial aims to comprehensively evaluate HSK44459 cream's potential as a treatment for plaque psoriasis, while also characterizing its safety, tolerability, and PK properties in both healthy individuals and patient populations.

Conditions

  • Psoriasis

Interventions

  • HSK44459 CreamDrug

    HSK44459 Cream

  • VehicleDrug

    HSK44459 Vehicle

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants Achieving Psoriasis Area Severity Index 75 (PASI-75)Time frame: Baseline (Day 1) and Week 8

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Hangzhou First People's Hospital

    Hangzhou, Zhejiang, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.